Pick Today's Price Range Low-High... Just for Fun, page-506

First 506 Last

Share
Profile

Follow
DocMcstuffins

8,130 Posts.

1408

14/05/24

18:48

Post #: 73821945
Share

Originally posted by imback: ↑

I strongly value the judgment of those experienced with the FDA who are also privy in the MSB meetings with the FDA and understand all the remaining issues FDA has with the submission (we unfortunately don't).

If that privileged information and FDA expertise results in hundreds of thousands being spent on MSB shares by them, then it would be incredibly foolish to dismiss that smoking gun. If you have access to that same information (which I personally don't) then sure go ahead and research this in detail and come up with your own conclusions.

It's not a sole reason for anyone to invest based on director buying but it's certainly adds a piece to the difficult puzzle to solve as to whether MSB gets a aGVHD approval on its next submission. To wait until the puzzle is solved, is a different type of investor mentality, one I am not prepared to engage given the time commitment I have put into researching this company. That investing strategy is for mums and dads superfunds and index hugging funds, along with risk averse investors who are OK to see a drawdown as long as they are on a winner. eg PNV

That's why it baffles me no end why those who have spent so much time here pushing that the approval will not be gained do not short the stock. It's an incredible waste of human resources as an investor to not take action on a well researched, firmly held belief. The inconsistency is beyond puzzling and probably why they receive so much flack from MSB investors.

Expand

I would never short a stock so driven by hype, the share price behaves irrationally - just look at it recently.

Not a gambling man.

We've all got our own strategies. Fingers crossed MSB has enough evidence to get approval, it's about time.

MSB Price at posting: $1.07 Sentiment: Sell Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

NOX

Noxopharm gets HERACLES autoimmune trials started with first human doses

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

IMU

Wednesday's HotCopper trends: Imugene cap raise, Lumos distribution deal | July 16

LIS

Li-S Energy the latest microcap to pivot to US defence market

LDX

Lumos Diagnostics surges 140% on major US contract deal

First 506 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.71		Change 0.010(0.59%)		Mkt cap ! $2.163B

Open	High	Low	Value	Volume
$1.68	$1.71	$1.64	$2.630M	1.573M

Buyers (Bids)

No.	Vol.	Price($)
33	35549	$1.71

Sellers (Offers)

Price($)	Vol.	No.
$1.71	27530	20

View Market Depth

No.	Vol.	Price($)
23	24559	1.705
23	27194	1.700
16	63641	1.695
11	48717	1.690
15	119195	1.685

Price($)	Vol.	No.
1.710	25862	9
1.715	55252	11
1.720	92816	16
1.725	84056	11
1.730	118768	13

Last trade - 14.27pm 16/07/2025 (20 minute delay)

MSB (ASX) Chart

Pick Today's Price Range Low-High... Just for Fun, page-506

Noxopharm gets HERACLES autoimmune trials started with first human doses

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

Wednesday's HotCopper trends: Imugene cap raise, Lumos distribution deal | July 16

Li-S Energy the latest microcap to pivot to US defence market

Lumos Diagnostics surges 140% on major US contract deal

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Pick Today's Price Range Low-High... Just for Fun, page-506

Top Stories

Noxopharm gets HERACLES autoimmune trials started with first human doses

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

Wednesday's HotCopper trends: Imugene cap raise, Lumos distribution deal | July 16

Li-S Energy the latest microcap to pivot to US defence market

Lumos Diagnostics surges 140% on major US contract deal

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News